Does Medicare cover Mounjaro and Zepbound (tirzepatide)?

Medicare covers Mounjaro for Type 2 diabetes but does NOT cover Zepbound for weight loss. Both drugs have the same active ingredient (tirzepatide) but are sold under different brand names for different FDA-approved uses, and that distinction determines Medicare coverage.

The two brands explained:

• Mounjaro (tirzepatide): FDA-approved for Type 2 diabetes. Manufactured by Eli Lilly. Has been Medicare Part D-covered since 2022 for the diabetes indication.

• Zepbound (tirzepatide): Same active ingredient. FDA-approved (December 2023) for chronic weight management in adults with obesity or overweight with at least one weight-related health condition. Marketed by Eli Lilly to a different patient population at a similar price.

Why coverage differs:

Medicare Part D's enabling statute (Medicare Modernization Act of 2003, Section 1860D-2(e)(2)) explicitly excludes weight-loss drugs from Part D coverage. This blanket exclusion has been in place since Part D launched in 2006.

• Mounjaro for diabetes → Medicare-covered
• Zepbound for weight loss → NOT Medicare-covered (federal statutory exclusion)

The Wegovy exception (and Zepbound implications):

In March 2024, CMS expanded Medicare Part D coverage to include Wegovy (semaglutide) when prescribed specifically for cardiovascular risk reduction in patients with established cardiovascular disease and obesity. This is a narrow expansion based on Wegovy's FDA-approved cardiovascular indication.

The expansion does NOT cover:
- Weight loss alone
- Other GLP-1s for non-cardiovascular indications
- Zepbound (which doesn't have an FDA cardiovascular indication as of 2026)

If you have Type 2 diabetes:

Mounjaro for diabetes is covered, but specifics depend on your Part D plan's formulary:

• Tier placement: Most plans place Mounjaro on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Some on Tier 5 (specialty). Lower tiers = lower copay.

• Prior authorization: Almost all Part D plans require PA. Your doctor must document Type 2 diabetes diagnosis (HbA1c history, prior treatments, etc.).

• Step therapy: Many plans require you to try metformin (and often a sulfonylurea or DPP-4 inhibitor) before Mounjaro. If those failed or aren't tolerated, Mounjaro becomes accessible.

• Quantity limits: Most plans cover the standard dosing schedule but may require additional PA for max-dose tier.

• 2026 cost: Out-of-pocket varies widely — $25/month copay on best plans, $200+/month copay on others. Annual exposure capped at $2,000 with the new Part D out-of-pocket cap.

If you don't have Type 2 diabetes but want Zepbound for weight loss:

Medicare Part D will not cover Zepbound. Options:

1. Pay out of pocket. Retail cost: ~$1,000–$1,300/month. Manufacturer coupons may not be available for Medicare beneficiaries (Anti-Kickback Statute restrictions).

1. Lilly Self-Pay program. Eli Lilly offers Zepbound at a reduced cash price (~$349–$549/month) via direct purchase from Lilly's pharmacy. May be the most affordable path.

1. Switch to Wegovy if you have cardiovascular disease. If you have established CVD + obesity, Wegovy may be Medicare-covered for the cardiovascular indication. Talk to your doctor about whether your situation qualifies.

1. Compounded tirzepatide (with major caveats). Some compounding pharmacies offer compounded versions at lower cost. As of 2026, the FDA has restricted compounding of tirzepatide following the resolution of the shortage. Quality and legality vary; consult your doctor.

1. Bariatric surgery may be covered. Medicare covers some bariatric surgery for severe obesity meeting specific criteria (BMI ≥35 with comorbidities or BMI ≥40). Different cost structure than ongoing medication.

1. Lobby Congress. Bills have been introduced repeatedly (Treat and Reduce Obesity Act) to expand Medicare coverage of obesity treatments, including weight-loss medications. As of mid-2026, none has passed.

Comparing your Part D plan options for Mounjaro:

If you're a Type 2 diabetic who takes Mounjaro:

1. List Mounjaro and your other medications
2. Use Medicare.gov Plan Finder — enter your full medication list; the tool will rank Part D plans by total annual cost
3. Look at the lowest 3 plans for Mounjaro tier placement specifically
4. Confirm prior auth requirements — some plans have lighter PA than others for the same drug
5. Check pharmacy network — preferred pharmacies often have lower copays than standard pharmacies

The difference between the best and worst Part D plan for someone on Mounjaro can be $1,500–$3,000/year in out-of-pocket cost.

Special situations:

• Dual-eligibles (Medicare + Medicaid): Mounjaro coverage often more generous; Medicaid may also cover Zepbound for weight loss in some states.
• Veterans: VA coverage rules differ from Medicare; Zepbound may be covered for weight loss under specific VA criteria.
• Manufacturer assistance: Eli Lilly's patient assistance for Mounjaro is more limited for Medicare beneficiaries due to federal anti-kickback rules.

Watch for 2027: The Inflation Reduction Act lets Medicare negotiate prices for top-spend drugs. GLP-1s are likely candidates in upcoming rounds. Coverage and cost may change significantly post-2027.

What to do next: Call (866) 534-1886 or [look up your specific medications on every Part D plan in your ZIP](/tools/drug-pricing/). We'll find the lowest-cost plan for your situation including any GLP-1 considerations. Free.